Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome
NCT06477653Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dupilumab in hypereosinophilic syndrome (HES), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Clinical improvement on dupilumab therapy as assessed by HES-Most Bothersome Symptom and HES-Symptom Inventory at 24 weeks. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT06477653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477653.